I didn’t hear Garnick (or anyone else) mention the HCV “program” on today’s CC. So, to the extent that executives previously touted the Bavi HCV data as “highly promising,” they were indeed misleading investors.
"Having personally been involved in the evaluation of over 30 Phase II trials over my career, none of which ever achieved statistical significance, including many of today's blockbuster biotech products"
I was at Genentech for 9 of his 17 years, and was in clinical development, not a dept mgr of regulatory(regulatory had no role in analysis of trial data)
I can think of 10+ ph 2 trials at genentech that reached statistical significance during his time. Why would he say that?
Market Data 
Markets 
AI
